105 related articles for article (PubMed ID: 7934140)
1. Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.
Armstrong SG; Browman GP; Benger AM; Meyer RM; McKay KL; Singh G
Leuk Res; 1994 Sep; 18(9):659-64. PubMed ID: 7934140
[TBL] [Abstract][Full Text] [Related]
2. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
[TBL] [Abstract][Full Text] [Related]
3. [A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
Shiga Y; Shichishima T; Aikawa K; Gotoh J; Furukawa T; Yamagiwa A; Ishibashi T; Maruyama Y
Rinsho Ketsueki; 1994 May; 35(5):501-5. PubMed ID: 8028198
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
[No Abstract] [Full Text] [Related]
5. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
Al Bahar S; Pandita R; Bavishi K; Savani B
Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy of adult ANLL].
Kyo T; Maehama S
Rinsho Ketsueki; 1989 Aug; 30(8):1157-62. PubMed ID: 2601024
[TBL] [Abstract][Full Text] [Related]
7. [The curative treatment of adult acute nonlymphocytic leukemia].
Uzuka Y; Saito Y
Rinsho Ketsueki; 1989 Aug; 30(8):1163-6. PubMed ID: 2601025
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
[TBL] [Abstract][Full Text] [Related]
9. Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside.
Balaban EP; Cox JV; Schneider NR; Harth CA; Haley BB; Sheehan R; Frenkel EP
Am J Hematol; 1988 Oct; 29(2):79-84. PubMed ID: 3189306
[TBL] [Abstract][Full Text] [Related]
10. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.
Stone RM; Maguire M; Goldberg MA; Antin JH; Rosenthal DS; Mayer RJ
Blood; 1988 Mar; 71(3):690-6. PubMed ID: 3422828
[TBL] [Abstract][Full Text] [Related]
11. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Dekker AW; Nieuwenhuis HK; Verdonck LF
Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study.
Evans C; Winkelstein A; Rosenfeld CS; Zeigler ZR; Shadduck RK
Cancer; 1990 Jun; 65(12):2624-30. PubMed ID: 2340464
[TBL] [Abstract][Full Text] [Related]
13. Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Yokoyama Y; Futagami M; Fukushi Y; Sakamoto T; Higuchi T; Fujii S; Sato S; Takami H; Saito Y
Arch Gynecol Obstet; 2000 Apr; 263(4):206-7. PubMed ID: 10834334
[TBL] [Abstract][Full Text] [Related]
14. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Wells RJ; Gold SH; Krill CE; Cornelius AS; Byrd RL; Ruymann FB; Feusner J; White ML; Cairo MS
Leukemia; 1994 Oct; 8(10):1626-30. PubMed ID: 7934157
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.
Gruber A; Liliemark E; Tidefelt U; Paul C; Björkholm M; Peterson C; Liliemark J
Leuk Res; 1995 Oct; 19(10):757-61. PubMed ID: 7500654
[TBL] [Abstract][Full Text] [Related]
16. The role of post-remission chemotherapy for older patients with acute myelogenous leukemia.
Abou-Jawde RM; Sobecks R; Pohlman B; Rybicki L; Advani A; Sekeres M; Kalaycio M
Leuk Lymphoma; 2006 Apr; 47(4):689-95. PubMed ID: 16690528
[TBL] [Abstract][Full Text] [Related]
17. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
[No Abstract] [Full Text] [Related]
18. [Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
Evensen SA; Brinch L; Wisløff F
Tidsskr Nor Laegeforen; 1989 Jun; 109(19-21):2004-6. PubMed ID: 2749689
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
MacCallum PK; Davis CL; Rohatiner AZ; Lim J; Gupta RK; Whelan JS; Price CG; Evans ML; Amess JA; Leahy M
Leukemia; 1993 Oct; 7(10):1496-9. PubMed ID: 8412309
[TBL] [Abstract][Full Text] [Related]
20. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
Steuber CP; Civin C; Krischer J; Culbert S; Ragab A; Ruymann FB; Ravindranath Y; Leventhal B; Wilkinson R; Vietti TJ
J Clin Oncol; 1991 Feb; 9(2):247-58. PubMed ID: 1988573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
